title: Relationship between expression of NADPH oxidase 2 and invasion and prognosis of human gastric cancer.
abstract: OBJECTIVE
  To assess the expression and prognostic value of nicotinamide adenine dinucleotide phosphate oxidase 2 (NOX2) in gastric cancer, and its correlation with vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR).
  
  
  METHODS
  Tumor and adjacent tissues were obtained from 123 patients who underwent radical surgery for gastric cancer at Renmin Hospital of Wuhan University from 2008-2009. The expression of NOX2, VEGF, EGFR and CD68 in tumor tissues was detected by immunohistochemistry. The expression of NOX2 in gastric cancer and adjacent tissues was detected by Western blot analysis. Spearman(')s correlation was performed to elucidate the relationship of NOX2 with VEGF and EGFR. The Kaplan-Meier method was used to calculate survival time, and the log-rank test was used to evaluate differences in survival. Cox's proportional hazards regression model was applied in a stepwise manner to analyze the independent prognostic factors.
  
  
  RESULTS
  NOX2 exhibited positive expression in 47.2% (58/123) of the gastric cancer tissues. Western blot analysis revealed that NOX2 was up-regulated in tumor tissues compared to the adjacent tissue [39.0% (48/123)]. Immunohistochemistry staining revealed that CD68, which is a specific marker of macrophages, and NOX expression presented a similar localization and staining intensity. The expression of NOX2 was positively correlated with that of VEGF and EGFR. Comparison of the 5-year survival rates of the NOX2 positive and NOX2 negative groups showed that the NOX2 positive group presented a poor prognosis.
  
  
  CONCLUSIONS
  NOX2 positively correlates with the levels of VEGF and EGFR. NOX2 may be used as a new biomarker and a potential therapeutic target for gastric cancer.
authors.affiliation: Peng Wang, Qiao Shi, Jia Yu, Teng Zuo, Fang-Chao Mei, Wei-Xing Wang, Department of Hepatobiliary Surgery, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei Province, China.
authors.forename: Peng
authors.initials: P
authors.lastname: Wang
authors.affiliation: Peng Wang, Qiao Shi, Jia Yu, Teng Zuo, Fang-Chao Mei, Wei-Xing Wang, Department of Hepatobiliary Surgery, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei Province, China.
authors.forename: Qiao
authors.initials: Q
authors.lastname: Shi
authors.affiliation: Peng Wang, Qiao Shi, Jia Yu, Teng Zuo, Fang-Chao Mei, Wei-Xing Wang, Department of Hepatobiliary Surgery, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei Province, China.
authors.forename: Wen-Hong
authors.initials: WH
authors.lastname: Deng
authors.affiliation: Peng Wang, Qiao Shi, Jia Yu, Teng Zuo, Fang-Chao Mei, Wei-Xing Wang, Department of Hepatobiliary Surgery, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei Province, China.
authors.forename: Jia
authors.initials: J
authors.lastname: Yu
authors.affiliation: Peng Wang, Qiao Shi, Jia Yu, Teng Zuo, Fang-Chao Mei, Wei-Xing Wang, Department of Hepatobiliary Surgery, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei Province, China.
authors.forename: Teng
authors.initials: T
authors.lastname: Zuo
authors.affiliation: Peng Wang, Qiao Shi, Jia Yu, Teng Zuo, Fang-Chao Mei, Wei-Xing Wang, Department of Hepatobiliary Surgery, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei Province, China.
authors.forename: Fang-Chao
authors.initials: FC
authors.lastname: Mei
authors.affiliation: Peng Wang, Qiao Shi, Jia Yu, Teng Zuo, Fang-Chao Mei, Wei-Xing Wang, Department of Hepatobiliary Surgery, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei Province, China.
authors.forename: Wei-Xing
authors.initials: WX
authors.lastname: Wang
mesh_terms: D015703:Antigens, CD / Q000032:analysis; D015214:Antigens, Differentiation, Myelomonocytic / Q000032:analysis; D014408:Biomarkers, Tumor / Q000032:analysis*; D015153:Blotting, Western; D002465:Cell Movement; D066246:ErbB Receptors / Q000032:analysis; D005260:Female; D005743:Gastrectomy; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008297:Male; D008562:Membrane Glycoproteins / Q000032:analysis*; D008875:Middle Aged; D000074662:NADPH Oxidase 2; D019255:NADPH Oxidases / Q000032:analysis*; D009361:Neoplasm Invasiveness; D011237:Predictive Value of Tests; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D012307:Risk Factors; D013274:Stomach Neoplasms / Q000201:enzymology* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D013997:Time Factors; D016896:Treatment Outcome; D015854:Up-Regulation; D042461:Vascular Endothelial Growth Factor A / Q000032:analysis; D000097382:CD68 Molecule
chemical_list: D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D014408:Biomarkers, Tumor; D066246:ErbB Receptors; D008562:Membrane Glycoproteins; D000074662:NADPH Oxidase 2; D019255:NADPH Oxidases; D042461:Vascular Endothelial Growth Factor A; C067980:CD68 antigen, human; D000097382:CD68 Molecule; C467484:VEGFA protein, human; C056558:CYBB protein, human; C512478:EGFR protein, human
keywords: Epidermal growth factor receptor; Macrophages; NADPH oxidase 2; Prognosis; Survival time; Vascular endothelial growth factor